Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
AssigneeAstraZeneca AB
InventorsJames Thomas LYNCH, Ho Man CHAN
Life of this patent
Estimating the term…
Abstract
The present specification relates to methods of treatment of wild type MTAP gene cancers comprising administering a MTA synergistic PRMT5 inhibitor to a patient in need thereof.
Claims18
A method of treatment of cancer comprising administering a MTA synergistic PRMT5 inhibitor to a patient in need thereof, wherein the patient has been identified as having a cancer in which wild type MTAP gene has been silenced.
A MTA synergistic PRMT5 inhibitor for use in the treatment of cancer, wherein the cancer is characterised as being wild type MTAP gene silenced.
A MTA synergistic PRMT5 inhibitor for use in the manufacture of a medicament, wherein the medicament is for use in the treatment of a cancer that is wild type MTAP gene silenced.
A pharmaceutical composition comprising a MTA synergistic PRMT5 inhibitor for use in the treatment of cancer, wherein the cancer is characterised as being wild type MTAP gene silenced.
A kit comprising a MTA synergistic inhibitor and instructions for its use in the treatment of a MTAP gene silenced cancer.
A method of treatment of cancer comprising the steps of i) analysing a sample obtained from a patient in need of treatment that they have a cancer that is wild type MTAP gene silenced;
- and ii) administering a therapeutically effective amount of a MTA synergistic PRMT5 inhibitor to the patient in need of treatment.
A method of identifying a patient that will benefit from treatment with a MTA synergistic PRMT5 inhibitor, the method comprising the step of identifying that a sample obtained from the patient is wild type MTAP gene silenced.
A method of identifying a wild type MTAP gene silenced tumour comprising the step of identifying that relevant tumour cells in a sample obtained from the patient exhibit reduced MTAP protein in their nuclei and their cytoplasm by performing a immunohistochemical assay for MTAP protein.
Dependencies are inferred from the claim text.